Jupiter Topco LLC Invests $9.03 Million in DaVita Inc. $DVA

Jupiter Topco LLC purchased a new stake in DaVita Inc. (NYSE:DVA) during the 2nd quarter, HoldingsChannel reports. The fund purchased 40,588 shares of the company’s stock, valued at approximately $9,030,000.

Several other hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of DaVita in the 2nd quarter valued at $547,520,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of DaVita by 114.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of DaVita during the 2nd quarter worth about $101,127,000. Norges Bank bought a new position in DaVita during the 4th quarter valued at about $49,164,000. Finally, Corient Private Wealth LLC boosted its position in DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after buying an additional 335,809 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Performance

NYSE:DVA opened at $180.72 on Monday. The company has a market cap of $11.53 billion, a price-to-earnings ratio of 14.79, a P/E/G ratio of 0.47 and a beta of 0.88. The stock’s fifty day moving average price is $211.96 and its two-hundred day moving average price is $183.37. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same period last year, the firm earned $2.95 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts predict that DaVita Inc. will post 14.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the topic of several research analyst reports. TD Cowen raised shares of DaVita from a “hold” rating to a “buy” rating and upped their price objective for the stock from $201.00 to $220.00 in a research note on Friday, August 7th. Barclays boosted their target price on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. UBS Group raised their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Truist Financial cut their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, DaVita has an average rating of “Hold” and a consensus price target of $221.75.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.90% of the stock is currently owned by insiders.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.